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Tight control of the tyrosine kinase activity of c-Src is critical for regulating its oncogenic potential. In a recent
issue of Molecular Cell, Oneyama et al. (2008a) report that the membrane-bound adaptor protein Cbp (also
known as PAG) can suppress c-Src-mediated cell transformation and tumorigenesis by binding and seques-
tering c-Src within lipid rafts. Cbp is also a raft-associated binding partner for Csk, a negative regulator of
c-Src. However, the authors show that Cbp-mediated Src suppression is Csk independent. These findings
suggest that Cbp is a tumor suppressor whose expression is downregulated during Src-driven cancer
progression.Src family kinases (SFKs) are membrane-
bound tyrosine protein kinases that share
a common domain structure. The found-
ing member of the family, Src, was origi-
nally identified as a retroviral oncoprotein
that induces transformation of avian cells
and sarcoma formation in chickens. It is
now well established that the cellular
proto-oncoprotein c-Src plays an influen-
tial role in human cancers. Increased
levels of c-Src protein and/or tyrosine
kinase activity have been detected in mul-
tiple tumor types, including breast, colon,
lung, head and neck, and pancreatic can-
cers (Ishizawar and Parsons, 2004). Src
activation promotes tumor progression,
metastasis, and angiogenesis, while
blockade of Src kinase activity results in
decreased tumor cell proliferation, migra-
tion, and invasion. These findings have
served as an impetus for the development
of Src kinase inhibitors, several of which
are currently in clinical trials for thera-
peutic treatment of a variety of human
cancers.The kinase activity of SFKs is tightly
regulated. A critical negative regulatory
tyrosine resides in the C-terminal tail of
all SFKs (Tyr527 in c-Src). When Tyr527
is phosphorylated, c-Src is inactive.
Dephosphorylation of Tyr527, or mutation
of Tyr527 to Phe, activates c-Src and
induces cellular transformation. Crystallo-
graphic studies have revealed that the
structural basis for c-Src regulation invol-
ves intramolecular interactions between
phospho-Tyr527 and the SH2 domain,
and between the SH3 domain and a poly-
proline-rich region. As a result, the kinase
domain is maintained in a closed, inactive
conformation in resting cells.
The kinase that phosphorylates Tyr527
is Csk, C-terminal Src kinase. Csk con-
tains an SH3, SH2, and kinase domain
but lacks the N-terminal membrane-bind-
ing motif (SH4) found in SFKs. Thus, a
mechanism must exist to allow cytosolic
Csk to gain access to its membrane-
bound substrate. In 2000, two groups
identified a transmembrane protein, CbpCancer(also called PAG), that binds Csk (Brdicka
et al., 2000; Kawabuchi et al., 2000).
Phosphorylation of Cbp by SFKs serves
to recruit Csk to membrane-bound Cbp.
Csk then phosphorylates and conse-
quently inactivates membrane-bound
SFKs.
Given this neatly intertwined set of re-
actions, one might assume that the ability
of Cbp to regulate SFKs is dependent on
Csk. However, a recent paper in Molecu-
lar Cell (Oneyama et al., 2008a) provides
several new twists to this scenario. First,
Oneyama et al. show that Cbp can func-
tion independently of Csk. The authors
used mouse embryonic fibroblasts de-
rived from Csk/ mice. When c-Src is
expressed in these cells, it is activated
and promotes transformation (Oneyama
et al., 2008b). The authors first noted
that levels of endogenous Cbp mRNA
and protein were reduced when activated
c-Src was expressed. They then made
the seminal observation that overexpres-
sion of exogenous Cbp reversed theCell 13, June 2008 ª2008 Elsevier Inc. 469
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PreviewsFigure 1. Csk-Independent Inactivation of c-Src by Raft-Associated Cbp
Membrane-bound c-Src can be activated by growth factor receptors, dephosphorylation of Tyr527, and/
or binding of SH2 or SH3 ligands. Activated c-Src phosphorylates Cbp and is then recruited to lipid rafts.
When associated with raft-bound Cbp, c-Src cannot access its substrates and is incapable of inducing
cellular transformation and tumorigenesis. Cbp inactivation by downregulation, dephosphorylation, or
depalmitoylation of Cbp could reactivate c-Src.oncogenic effects of c-Src. Transformed
cell morphology was reverted and growth
in soft agar was reduced in vitro, and
a striking suppression of tumor formation
in nude mice occurred in vivo.
A second surprise came when the au-
thors examined the mechanism of Cbp-
mediated suppression. Cbp had no effect
on intrinsic c-Src tyrosine kinase activity.
Instead, Cbp expression altered c-Src
localization. Cbp is a palmitoylated pro-
tein that concentrates in lipid rafts, mem-
brane microdomains that are enriched in
cholesterol and have different biophysical
properties from the bulk plasma mem-
brane. Oneyama et al. demonstrated that
the SH2 domain of c-Src binds to tyro-
sine-phosphorylated Cbp. This resulted
in recruitment of nearly all of the c-Src to
the raft fraction, where it was associated
with Cbp (Figure 1).
How does a change in subcellular
localization regulate SFK function? The
authors found that neither raft-associ-
ated c-Src nor raft-associated Fyn, an-
other SFK, was able to transform cells.
Moreover, redistribution of Fyn to non-
raft fractions, by mutating a Fyn palmi-
toylation site, increased transforming ac-
tivity. The association of c-Src and Fyn470 Cancer Cell 13, June 2008 ª2008 Elseviwith rafts and/or raft-associated Cbp
apparently blocks their ability to phos-
phorylate key substrates required for
transformation.
If Cbp efficiently sequesters and func-
tionally inactivates Src, one would predict
that Cbp could act as a tumor suppressor
in cells whose oncogenic potential is
driven by activated c-Src. Indeed, loss
of Cbp expression was noted in breast
and colon cancer cell lines that overex-
press c-Src. Conversely, overexpression
of Cbp in a colon cancer cell line resulted
in association of Cbp and c-Src, c-Src in-
activation, and strong inhibition of tumor
formation in nude mice.
Implications and Complications
The findings of Oneyama et al. illustrate
the multifunctional ability of Cbp to sup-
press Src function in Csk-dependent
and -independent modes. Csk activity is
decreased in some colorectal cancers,
implying that Csk-independent regulation
of Src by Cbp may be operative in human
tumors. These findings also predict that
downregulation of Cbp should occur in
order for Src-driven tumor formation to
progress. c-Src induces Cbp loss at theer Inc.transcriptional level, but the mechanisms
responsible are unknown.
Cbp is likely to have a more general role
in regulating normal as well as oncogenic
signaling by receptor protein tyrosine ki-
nases. EGFR, PDGFR, and FGFR phos-
phorylate Cbp in response to ligand. For
EGFR, this occurs via c-Src (Jiang et al.,
2006). Overexpression of Cbp blocks
EGFR-mediated c-Src activation, signal-
ing, and cell transformation, while loss of
Cbp function has the reverse effect.
Thus, Cbp may regulate the synergistic
interaction between c-Src and EGFR in
breast cancer.
Cbp contains multiple potential sites
for protein:protein interaction that enable
it to serve as a scaffold for signaling pro-
teins. The cytoplasmic domain has two
proline-rich SH3-binding motifs and ten
tyrosines, nine of which are SFK target
phosphorylation sites. Phosphorylated
Cbp can recruit the SH2 domain-contain-
ing proteins Csk, SFKs, and SOCS1 (Ing-
ley, 2008). In addition, Cbp binds to
EBP50, an ezrin-binding protein, thereby
linking Cbp-containing rafts to the actin
cytoskeleton.
How can Cbp function be turned off
(Figure 1)? Dephosphorylation of Cbp
would result in dissociation of the bound
SFK and other signaling proteins. The
phosphatase (or phosphatases) that de-
phosphorylates Cbp has not been defi-
nitely identified, although SHP2 and
CD45 may play a role. Alternatively, Cbp
could be removed from lipid rafts by de-
palmitoylation. Many palmitoylated pro-
teins undergo dynamic cycles of palmi-
toylation/depalmitoylation (Resh, 2006).
Depalmitoylation would promote redistri-
bution of Cbp, and Cbp-associated pro-
teins, from raft domains into the bulk
plasmamembrane, where signaling prop-
erties may differ.
The findings of Oneyama et al. compli-
cate our understanding of lipid rafts: do
they play a positive or negative regulatory
role in signal transduction? There is ample
evidence in the literature that rafts are pos-
itive hubs for signaling by activated recep-
tors and their associated SFKs. For exam-
ple, SFKs need to be localized in rafts to
mediate downstream signaling by immune
cell receptors (Resh, 2006). Moreover, two
recent studies have shown that SFKs are
active (Solheim et al., 2008) and can drive
cancer cell growth (Tauzin et al., 2008)
even when bound to raft-associated Cbp.
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PreviewsThe findings of Oneyama et al. stand
in stark contrast—raft-associated c-Src
was inactive. These discrepancies might
bedue to differences in theSFK, fatty acyl-
ation status, cell type, extent of Csk-Cbp
interaction, and/or association with differ-
ent subsets of rafts. Perhaps the best
way to reconcile these disparate findings
is to propose that Cbp can function as
both a positive and negative regulator of
SFKs. In this regard, the work of Oneyama
et al. broadens our appreciation of the
multiple levels at which SFK activity
and tumorigenesis can be regulated.REFERENCES
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